4SC to provide pre-medical data on vidofludimus in systemic lupus erythematosus at EULAR 2011 4SC AG , a advancement and discovery company of targeted small molecule medications for autoimmune and tumor diseases, will show pre-clinical data on vidofludimus – its lead small-molecule drug applicant against autoimmune diseases – in systemic lupus erythematosus at EULAR 2011, Europe’s largest scientific conference in rheumatic diseases, in London, UK, from May 25-28, 2011. Vidofludimus is usually a novel oral inhibitor of dihydroorotate dehydrogenase and of pro-inflammatory cytokine discharge including interleukin-17 as well as interferon-gamma which is definitely in Stage IIb development for rheumatoid arthritis and has finished a positive Phase IIa study in inflammatory bowel disease. Additionally, the drug candidate has been demonstrated to be highly active in pre-clinical models of further autoimmune illnesses such as multiple sclerosis, psoriasis, and transplant rejection How much amoxicillin do you give a dog? .
A primary final result event occurred in 233 of 395 patients in the cyclosporine group and in 230 of 396 in the control group . All-trigger mortality at 1 year was 7.1 percent in the cyclosporine group and 6.6 percent in the control group . The rate of initial worsening of heart failing or rehospitalization for heart failure at 12 months was equivalent in the cyclosporine group and the control group . Adverse left ventricular remodeling happened in 42.8 percent of the sufferers in the cyclosporine group and in 40.7 percent of these in the control group .). The rates of most other secondary scientific outcomes, including cardiogenic shock, recurrent myocardial infarction, unstable angina, stroke, and severe renal failure, were very similar in both groups at 1 year .